A Trial for Patients with PSA Recurrence after Surgery

Clinical Trial Title

A Trial to See What the Results Are for Radiation Therapy and Hormone Therapy vs Radiation Therapy With Enhanced Hormone Therapy With Enzalutamide for Patients With PSA Recurrence After Surgery (STEEL)

National Clinical Trial Number:

NCT03809000

Contact Information

Radiation Oncology

Clinical Trial Protocol Description:

The purpose of this study is to compare the usual treatment of radiation and hormone therapy with the usual treatment plus the study drug, enzalutamide. The addition of the study drug to the usual treatment could increase the time without disease progression.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have pathologically proven adenocarcinoma confirmed by prostatectomy performed within 10 years.
  • Have a PSA level (≥0.2 ng/mL) within 90 days prior to registration.
  • Have hemoglobin ≥9.0 g/dL, independent of transfusion and/or growth factors within 90 days prior to registration.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Dian Wang, MD

Contact Information

Radiation Oncology

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more